Show simple item record

dc.contributor.authorLynch, Rhoda
dc.contributor.authorDiggins, Eileen
dc.contributor.authorConnors, Susan
dc.contributor.authorZimmerman, Andrew W.
dc.contributor.authorSingh, Kanwaljit
dc.contributor.authorLiu, Hua
dc.contributor.authorTalalay, Paul
dc.contributor.authorFahey, Jed W.
dc.date2022-08-11T08:10:13.000
dc.date.accessioned2022-08-23T16:59:36Z
dc.date.available2022-08-23T16:59:36Z
dc.date.issued2017-10-26
dc.date.submitted2017-12-21
dc.identifier.citationGlob Adv Health Med. 2017 Oct 26;6:2164957X17735826. doi: 10.1177/2164957X17735826. eCollection 2017. <a href="https://doi.org/10.1177/2164957X17735826">Link to article on publisher's site</a>
dc.identifier.issn2164-9561 (Linking)
dc.identifier.doi10.1177/2164957X17735826
dc.identifier.pmid29147630
dc.identifier.urihttp://hdl.handle.net/20.500.14038/43624
dc.description.abstractIntroduction: Autism spectrum disorder (ASD) affects 1 in 68 children, is characterized by impaired social interaction and communication as well as restricted or repetitive behaviors, and varies widely with respect to its causes and presentations. There are no validated pharmacologic treatments for the core symptoms of ASD. The social, medical, and economic burdens of ASD on families and caregivers are profound. We recently showed in a small clinical trial that sulforaphane (SF) from broccoli sprouts could significantly reduce the behavioral symptoms of ASD. Methods: After we completed the intervention phase of the original trial (2011-2013), many caregivers used over-the-counter dietary SF supplements in order to attempt to maintain improvements similar to those noted during the intervention. We periodically followed the progress of study participants through the summer of 2016. Results: Families of 16 of the 26 subjects who received SF as part of the original study responded to requests for further information. Of these subjects, 6 did not continue taking SF supplements after the study. Nine of the 16 subjects are still taking an SF supplement and a 10th planned to. We present the edited testimonials of their caregivers in this case series. Conclusions: Many parents and caregivers articulated the positive effects of SF, both during the intervention phase and in the ensuing 3 years reported herein. These observations may contribute to understanding ASD and to treatments that may alleviate some of its symptoms. Diet- and supplement-based therapies deserve careful consideration for their potential to provide vital clinical as well as biochemical information about ASD.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=29147630&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672987/
dc.rightsCopyright The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectglucoraphanin
dc.subjectglucosinolate
dc.subjectisothiocyanate
dc.subjectprevention
dc.subjectMental Disorders
dc.subjectPediatrics
dc.subjectTherapeutics
dc.titleSulforaphane from Broccoli Reduces Symptoms of Autism: A Follow-up Case Series from a Randomized Double-blind Study
dc.typeJournal Article
dc.source.journaltitleGlobal advances in health and medicine
dc.source.volume6
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1194&amp;context=peds_pp&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/peds_pp/195
dc.identifier.contextkey11286422
refterms.dateFOA2022-08-23T16:59:36Z
html.description.abstract<p>Introduction: Autism spectrum disorder (ASD) affects 1 in 68 children, is characterized by impaired social interaction and communication as well as restricted or repetitive behaviors, and varies widely with respect to its causes and presentations. There are no validated pharmacologic treatments for the core symptoms of ASD. The social, medical, and economic burdens of ASD on families and caregivers are profound. We recently showed in a small clinical trial that sulforaphane (SF) from broccoli sprouts could significantly reduce the behavioral symptoms of ASD.</p> <p>Methods: After we completed the intervention phase of the original trial (2011-2013), many caregivers used over-the-counter dietary SF supplements in order to attempt to maintain improvements similar to those noted during the intervention. We periodically followed the progress of study participants through the summer of 2016.</p> <p>Results: Families of 16 of the 26 subjects who received SF as part of the original study responded to requests for further information. Of these subjects, 6 did not continue taking SF supplements after the study. Nine of the 16 subjects are still taking an SF supplement and a 10th planned to. We present the edited testimonials of their caregivers in this case series.</p> <p>Conclusions: Many parents and caregivers articulated the positive effects of SF, both during the intervention phase and in the ensuing 3 years reported herein. These observations may contribute to understanding ASD and to treatments that may alleviate some of its symptoms. Diet- and supplement-based therapies deserve careful consideration for their potential to provide vital clinical as well as biochemical information about ASD.</p>
dc.identifier.submissionpathpeds_pp/195
dc.contributor.departmentDepartment of Pediatrics, Division of Pediatric Neurology
dc.source.pages2164957X17735826


Files in this item

Thumbnail
Name:
Sulforaphane_2164957x17735826.pdf
Size:
329.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Except where otherwise noted, this item's license is described as Copyright The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).